



PROGRAM




CANADIAN
LIVER
MEETING

MAY 24 – 26, 2019 | HÔTEL BONAVENTURE | MONTRÉAL, QUÉBEC

OVERALL CONFERENCE LEARNING OBJECTIVES

Following attendance at the conference, participants will be able to:

- Expand their knowledge on the latest evidence for the treatment and management of patients with liver disease, pre- and post-liver transplant, hepatocellular carcinoma, viral hepatitis, non-alcoholic fatty liver, alcohol, and autoimmune liver disease
- Explain strategies and treatment approaches for the elimination of Hepatitis C in Canada and abroad, including public health and epidemiological perspectives for managing HCV infection
- Describe basic science mechanisms at work behind liver fibrosis and HCC development
- Review case studies and clinical practice concerns commonly seen in hepatology nursing, and discuss strategies for improving nursing research and patient care
- Obtain an overview of research and evidence presented at AASLD and other international liver meetings
- Expand their network of contacts within the Canadian hepatology community in order to increase opportunities for scholarship, professional collaboration, integrated and interdisciplinary clinical practice, and advocacy for better patient care



CANADIAN
LIVER
MEETING



8TH CANADIAN SYMPOSIUM ON HEPATITIS C

FRIDAY, MAY 24, 2019

7:15 am – 7:00 pm | Conference-Level Foyer
Registration Open



8:00 – 8:15 am | Montréal 4-5
WELCOME AND INTRODUCTIONS
Naglaa Shoukry, Université de Montréal

8:15 – 9:51 am | Montréal 4-5

SESSION 1 BIOMEDICAL RESEARCH

Co-Chairs: Rod Russell and Vanessa Meier-Stephenson

Following this session, participants will be able to:

-  Review current HCV biomedical research
-  Analyze future challenges in understanding the biology of HCV

8:15 – 8:35 am
Remaining Challenges in HCV Research
Ralf Bartenschlager, University of Heidelberg

8:35 – 8:55 am
Single-Cell RNA Sequencing to Describe the Cellular Microenvironment of the Liver
Sonya MacParland, University of Toronto

8:55 – 9:15 am
Questions and Panel Discussion

9:15 – 9:27 am
Targeting HCV-Induced Epigenetic Reprogramming for HCC Chemoprevention Post Cure
Nourine Hamdane, University of Strasbourg

9:27 – 9:39 am
Identification of the Domain to which miR122 and Other Small RNAs Annealing Promotes the HCV Lifecycle
Rasika Kunden, University of Saskatchewan

9:39 – 9:51 am
Analysis of Programmed Cell Death Induced by HCV Infection
Lingyan Wang, Memorial University



9:51 – 10:10 am | St. Laurent 1-3
Coffee Break

10:10 – 11:34 am | Montréal 4-5

SESSION 2 SOCIAL, CULTURAL, ENVIRONMENTAL, AND POPULATION HEALTH RESEARCH

Co-Chairs: Marina Klein and Abdool Yaseen

Following this session, participants will be able to:

-  Identify gaps and strategies for scaling-up HCV diagnosis, screening, and therapeutic strategies
-  Recognize barriers to HCV control in HIV/HCV connected patients and people who inject drugs

10:10 – 10:30 am
Diagnostic Testing for Hepatitis C Infection: Where Are We Now and What Does the Future Hold
Stuart C. Ray, Johns Hopkins University School of Medicine

10:30 – 10:50 am
Hepatitis C and HIV Testing from Dried Blood Spots: Simplifying Testing to Broaden Community Based Testing
John Kim, Public Health Agency of Canada

10:50 – 11:11 am
Questions and Panel Discussion

11:11 – 11:22 am
Estimation of an Individual-Level Deprivation Index for HIV/HCV Co-Infected Persons
Adam Palayew, McGill University

11:22 – 11:34 am
Opioid Agonist Treatment and Risk of Hepatitis C Virus Infection Among People Who Inject Drugs: The Overlooked Role of Dosage Adequacy
Andreea Adelina Artenie, Université de Montréal

11:34 – 1:00 pm | St. Laurent 1-3
Lunch and Poster Sessions
Posters will be evaluated between 12:00 – 1:00pm



FRIDAY, May 24, 2019 continued

1:00 – 2:36 pm | Montréal 4-5

SESSION 3 CLINICAL RESEARCH

Co-Chairs: Lisa Barrett and Sahar Saeed

Following this session, participants will be able to:

-  Appreciate the diagnostic approach to liver fibrosis staging and the management of HCC in HCV
-  Understand the remaining gaps in HCV treatment and linkage to care

1:00 – 1:20 pm

Risk of HCC Following Hepatitis C Treatment

Hashem B. El-Serag, Baylor College of Medicine

1:20 – 1:40 pm

Liver Fibrosis Staging in Hepatitis C

Keyur Patel, University Health Network

1:40 – 2:00 pm

Questions and Panel Discussion

2:00 – 2:12 pm

Never Too Old to be DAA Treated for Hepatitis C

Curtis Cooper, University of Ottawa

2:12 – 2:24 pm

Feasibility of Rapid Hepatitis C Point-of-Care RNA Testing and Linkage to Care at an Integrated Supervised Consumption Site in Toronto, Canada

Bernadette Lettner, South Riverdale Community Health Centre

2:24 – 2:36 pm

Engaging Vulnerable Treatment Naïve Persons Living with Hepatitis C in Same-Day Treatment

Shawn Greenan, Health PEI

2:36 – 2:56 pm | St. Laurent 1-3



Coffee Break

2:56 – 5:15 pm | Montréal 4-5

SESSION 4 HEALTH SERVICES RESEARCH

Co-Chairs: Naveed Janjua and Aysegul Erman

Following this session, participants will be able to:

-  Review challenges of hepatitis C elimination
-  Assess feasibility of HCV testing and linkage to care in different provincial and community settings

2:56 – 3:16 pm

Scaling Up HCV Screening and Diagnosis to Eliminate HCV

Jagpreet Chhatwal, Harvard Medical School

3:16 – 3:36 pm

Testing and Linkage with Care Strategies for HCV Among Immigrants and Newcomers

Christina Greenaway, McGill University

3:36 – 3:56 pm

Questions and Panel Discussion

3:56 – 4:08 pm

The Hepatitis C Virus (HCV) Cascade of Care in a Canadian Provincial Prison: Implications for HCV Micro-Elimination

Nadine Kronfli, McGill University

4:08 – 4:20 pm

State-Specific Direct Medical Costs of Hepatitis C in Ontario: A Population-Level Study

Alexander Haines, Toronto Health Economics and Technology Assessment Collaborative

4:20 – 4:32 pm

Assessment of Hepatitis C Screening Strategies in Different Community Settings in a Canadian Metropolitan Area

Camelia Capraru, Toronto Centre for Liver Disease/VIRCAN, UHN

4:32 – 5:15 pm

Engaging People with Lived Experience to Improve Hepatitis C Diagnosis and Linkage-to-Care in Programming and Research

Questions and Panel Discussion

Moderator: Chris Hoy, CATIE

Panel: Dopamine, Montréal, Quebec

Access Place, Prince Albert, Saskatchewan

Toronto Community Hepatitis C Program, Ontario

5:15 – 5:25 pm | Montréal 4-5

CANHEPC TRAINEE AWARDS CEREMONY

5:25 – 5:30 pm | Montréal 4-5

CANHEPC SYMPOSIUM CLOSING REMARKS

Selena Sagan and Giada Sebastiani, McGill University

CANADIAN LIVER MEETING

FRIDAY, MAY 24, 2019

5:30 – 5:40 pm | Montréal 4-5

CANADIAN LIVER MEETING OPENING REMARKS

Marc Bilodeau, Université de Montréal

5:40 – 6:30 pm | Montréal 4-5

BLUEPRINT TO INFORM HEPATITIS C ELIMINATION EFFORTS IN CANADA

Presenter/Moderator: Jordan Feld, University of Toronto

Panel: Melisa Dickie, CATIE

Lindsay Jennings, Prisoners HIV/AIDS Support Action Network

Julie Bruneau, Université de Montréal

Mel Krajden, University of British Columbia

Marina Klein, McGill University

6:30 pm | Foyer of St. Laurent 1-3

CANADIAN LIVER MEETING OPENING RECEPTION

SATURDAY, MAY 25, 2019

7:00 am – 4:00 pm

Registration Open

7:00 – 7:45 am

BREAKFAST SYMPOSIA

Registration required



Outremont 4

Difficult Cases in Treating Patients with Hepatitis C

Matthew Sadler, University of Calgary

Curtis Cooper, University of Ottawa

Following this session, participants will be able to:

-  Consider the components that make a case difficult in the DAA era
-  Explore the role of ribavirin




Outremont 5

Palliative Care in Patients with End-Stage Liver Disease

Cynthia Tsien, University of Ottawa

Susan Cuvelier, University of Manitoba

Following this session, participants will be able to:

-  Recognize all patients with end-stage liver disease who would benefit from palliative care
-  Identify the particular challenges in providing palliative care in liver disease
-  Manage specific complications of cirrhosis which impact patients' quality of life

SATURDAY, May 25, 2019 continued

8:00 – 9:15 am | Montréal 4-5




CONCURRENT SESSION

HCC BASIC / TRANSLATIONAL

Molecular Mechanisms of HCC in Viral Hepatitis

Ralf Bartenschlager, Heidelberg University




Following this session, participants will be able to:

-  Distinguish the magnitude of impact viral hepatitis has on liver cancer
-  Comprehend the main mechanisms of how hepatitis virus infection contributes to tumorigenesis
-  Identify the relevance of global control of viral hepatitis as a means to reduce liver cancer burden

Metabolic Profiling of HCC: In Vitro and In Vivo Models of HCC

Marc Bilodeau, Université de Montréal



Following this session, participants will be able to:

-  Review the main metabolic pathways important for cancer cells
-  Define and introduce the concept of the Warburg effect
-  Identify how these concepts can be used to diagnose/treat liver cancer in the future

The Role of the Inflammasome in Gastrointestinal Cancers and Liver Metastasis

Maya Saleh, McGill University




Following this session, participants will be able to:

-  Identify the role of the inflammasome in intestinal homeostasis, colitis, and colorectal cancer
-  Report on the functions of the innate immune system in cancer immunosurveillance in the liver

New Medical Therapies for HCC

Hélène Castel, Université de Montréal

Following this session, participants will be able to:

-  Distinguish the general mechanism of action of new medical therapies for HCC
-  Identify the target population for new medical therapies for HCC
-  Describe the main side effects of those new medical treatments

9:15 – 9:20 am

Room Change

8:00 – 9:15 am | Montréal 1-3




CONCURRENT SESSION

PUBLIC HEALTH

Innovative Approaches to Enhance Testing, Linkage to Care and Treatment for HCV Infection

Chairs: Naveed Janjua, British Columbia Centre for Disease Control, Canada; and Lesley Gallagher, CAHN, Canada

Following this session, participants will be able to:

-  Describe models of care to enhance testing, linkage to care and treatment of HCV infection in various settings and population groups
-  Discuss challenges and successes of establishing these HCV models of care
-  Outline future steps required to expand and scale-up these models

8:00 – 8:05 am

Introduction and Setting the Scene

Jason Grebely, Canadian Network on Hepatitis C and UNSW Sydney, Australia

8:05 – 8:15 am

Nurse Led HCV Micro- Elimination Outreach Project for People with Unstable Housing and Homelessness in Victoria BC

Tamara Barnett, Cool Aid

8:15 – 8:25 am

Enhancing Care for HCV Infection in Prisons in Eastern Canada

Lisa Barrett, Dalhousie University

8:25 – 8:35 am

Accelerated Pre-Treatment Evaluation for Persons Who Inject Drugs Disengaged from the Healthcare System in Montréal, Québec

Valérie Martel-Laferrrière, Université de Montréal

8:35 – 8:45 am

Nurse Practitioners as Site Champions in HCV Screening and Treatment in Family Health Teams in Ontario

Mia Biondi, Toronto Centre for Liver Disease, University Health Network

8:45 – 9:15 am

Panel Discussion

*Discussants: Jason Grebely
Naveed Janjua
and Presenters*

9:15 – 9:20 am

Room Change

SATURDAY, May 25, 2019 continued

9:20 – 10:15 am | Montréal 4-5

ORAL ABSTRACT PRESENTATIONS

VIRAL HEPATITIS

Incidence and Predictors of Flares after Stopping Nucleos(t)ide Analogue Therapy in HBeAg Negative Patients with Chronic Hepatitis B: Results from the Randomized Controlled STOP Study

Scott Fung, Toronto Centre for Liver Disease

Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Simple, Effective Regimen for the Treatment of Chronic Hepatitis C Patients: Integrated Analysis of 12 Clinical Practice Cohorts

Alnoor Ramji, University of British Columbia

Results of a Birth Cohort Hepatitis C Screening Program in an Academic Emergency Department in Canada

Camelia Capraru, Toronto Centre for Liver Disease/MIRCAN, UHN

Noninvasive Prediction of Esophageal Varices by Liver Stiffness Measurement and Platelet Count in 590 HIV-Infected Cirrhotic Patients With and Without HCV Coinfection: Multicenter Validation of Baveno VI Criteria

Giada Sebastiani, McGill University

Prenatal HBsAg Screening Rates and Follow-Up DNA Testing is Low in Ontario

Mia Biondi, Toronto Centre for Liver Disease, University Health Network

10:15 – 10:45 am

Break, Poster and Exhibit Viewing

9:20 – 10:15 am | Montréal 1-3

CAHN SESSION

Session Chair: Mary Guyton

9:20 – 9:25 am

Welcome




Donna Zukowski, CAHN President

9:25 – 9:50 am

Nutrition in Liver Disease: Practical Counselling Tips

Chantal Bemeur, Université de Montréal

Following this session, participants will be able to:





-  Define and identify malnutrition as a serious complication of liver disease
-  Inform on how to screen and detect malnutrition in patients with liver disease
-  Provide practical nutritional tips to optimize nutritional status in patients with liver disease

9:50 – 10:15 am

Hepatic Encephalopathy: Nursing Interventions

Elizabeth Lee, University Health Network, Toronto General Hospital

Following this session, participants will be able to:

-  Review the underlying pathophysiological mechanisms of hepatic encephalopathy
-  Recognize the impact of hepatic encephalopathy on relevant clinical outcomes
-  Review of clinical assessment tools used for screening of hepatic encephalopathy
-  Understand the importance of multidisciplinary collaboration in managing hepatic encephalopathy

10:15 – 10:45 am

Break, Poster and Exhibit Viewing



SATURDAY, May 25, 2019 continued

10:45 – 12:30 pm | Montréal 4-5

CONCURRENT SESSION

NEW CLINICAL DEVELOPMENTS

NAFLD

Saumya Jayakumar, UC San Diego

Following this session, participants will be able to:

- Recap the pathophysiology leading to the development of NASH and progression to fibrosis
- Review the current therapeutic regimens available for treatment of NASH
- Brief review of the emerging treatment options and trials underway for NAFLD and NASH

Alcohol

Gyongyi Szabo, University of Massachusetts Medical School

Following this session, participants will be able to:

- Understand the most recent updates in human clinical trials and management of disease in alcoholic hepatitis
- Learn about novel therapies in alcoholic hepatitis including treatment with anakinra, an IL-1 receptor antagonist

Viral Hepatitis

Mark Sulkowski, John Hopkins Medicine

Following this session, participants will be able to:

- Discuss current status of HCV elimination and therapeutic questions
- Describe developments in HBV cure

The Challenge of Fontan Associated Liver Disease

Beverly Kok, University of Alberta Hospital

Following this session, participants will be able to:

- Discuss the pathophysiology behind FALD
- Recognize the likely increase in frequency of this condition in time
- Explain the need for continued monitoring and surveillance

12:30 – 1:30 pm | St. Laurent 1-3

Lunch, Poster and Exhibit Viewing

10:45 am – 12:30 pm | Montréal 1-3

CONCURRENT SESSION

MECHANISMS OF LIVER INJURY AND REPAIR IN NAFLD AND VIRAL HEPATITIS

Immunopathogenesis of Hepatitis B

Adam Gehring, University of Toronto

Following this session, participants will be able to:

- Restate how serum cytokines have the power to guide immunological studies in well controlled clinical trials
- Discuss the power of longitudinal liver sampling to study pathogenesis and treatment intervention in chronic Hepatitis B
- Identify widespread transcriptional activation of liver leukocytes that is defined by an interferon signature

Analysis of Virus Induced Mechanisms of Programmed Cell Death

Rodney Russell, Memorial University

Following this session, participants will be able to:

- Define the mechanisms of inflammasome activation
- Explain virus-induced pyroptosis

The Liver as a Frontline Immune Organ

Craig Jenne, University of Calgary

Following this session, participants will be able to:

- Describe the central role the liver plays in the response to and clearance of bloodstream infections
- Explain the role of and interaction between various immune cell populations in the liver
- Report on the processes linking inflammation and coagulopathy

Insulin Signaling in NAFLD and NAFLD-Related HCC

Jennifer Estall, McGill University

Following this session, participants will be able to:

- Appreciate the importance of glucagon in efficient hepatic insulin signalling
- Consider low PGC-1alpha levels as a potential risk for NAFLD and liver cancer related to obesity

12:30 – 1:30 pm | St. Laurent 1-3

Lunch, Poster and Exhibit Viewing



SATURDAY, May 25, 2019 continued

1:30 – 3:00 pm | Montréal 4-5

CONCURRENT SESSION

PUBLIC HEALTH AND BEST PRACTISE CLINICAL MANAGEMENT

Nutrition Updates in NAFLD and Cirrhosis

Maitreyi Raman, University of Calgary

Following this session, participants will be able to:

- Discuss nutrition updates in the management of NASH
- Compare the role of sarcopenic obesity in the setting of NASH and cirrhosis
- Identify the role of the microbiome in the pathogenesis of NASH

Public Health Approaches In Childhood Obesity

Shazhan Amed, University of British Columbia

Following this session, participants will be able to:

- Describe a systems science approach to complex public health problems such as childhood obesity prevention
- Advocate for multi-sectoral participation to prevent childhood obesity and its serious complications
- Implement the Live 5-2-1-0 approach and resources in the clinical setting

Up-to-Date Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension

Samir Gupta, University of Toronto

Following this session, participants will be able to:

- Define the hepatopulmonary Syndrome and portopulmonary hypertension, including distinctions between them
- Describe management strategies for the hepatopulmonary Syndrome
- Discuss management strategies for portopulmonary hypertension

3:00 – 3:30 pm | St. Laurent 1-3

Break, Poster and Exhibit Viewing

1:30 – 3:00 pm | Montréal 1-3

CONCURRENT SESSION

EVOLVING EVIDENCE IN LIVER DISEASE PATHOGENESIS AND BEST CLINICAL MANAGEMENT

Novel Mechanisms Linking Blood Coagulation to Liver Injury and Regeneration

James Luyendyk, Michigan State University

Following this session, participants will be able to:

- Describe the basic concepts of the delicate rebalance of hemostasis in patients with chronic liver disease
- Discuss the basic mechanisms linking liver damage to progression of liver disease
- Define the role of clotting proteins in liver regeneration after liver resection

Overview of Hepatitis B Reactivation: Current Concepts, Molecular Mechanisms, and Management

Norah Terrault, Keck School of Medicine, USC

Following this session, participants will be able to:

- Describe the mechanistic underpinnings of HBV reactivation
- Identify the clinical settings when reactivation occurs, natural history, and outcomes
- Learn management strategies to prevent and treat HBV reactivation

Translational Research in Alcoholic Hepatitis

Gyongyi Szabo, University of Massachusetts Medical School

Following this session, participants will be able to:

- Understand the role of gut-liver axis, innate immune activation, and hepatocyte damage in the pathogenesis of alcoholic hepatitis.
- Identify the importance, clinical implication, and occasional limitations of preclinical studies in testing new therapeutic interventions in animal models of alcoholic hepatitis and alcoholic liver disease
- Recognize the potential of translational research in development of new biomarkers in alcoholic hepatitis.

HCV Treatment in HCC: Yes or No? A Debate

David Wong, University of Toronto vs. Kelly Burak, University of Calgary

Following this session, participants will be able to:

- Recognize the benefits of HCV eradication in cirrhotics
- Evaluate the association, or lack thereof, between direct acting antivirals and risk of hepatocellular carcinoma recurrence

3:00 – 3:30 pm | St. Laurent 1-3

Break, Poster and Exhibit Viewing

SATURDAY, May 25, 2019 continued

3:30 – 5:00 pm | Montréal 4-5

CASL-CLF SASS-KORTSAK LECTURE PEDIATRIC SYMPOSIUM

CASL-CLF Sass-Kortsak Lecture

Fernando Alvarez, CHU-Sainte Justine

Following this session, participants will be able to:

- Discuss current knowledge on autoimmune hepatitis pathogenesis
- Assess and explain new putative treatments and the mechanisms of action of the treatments

Biliary Atresia in Long-Term Kasai Survivors

Richard Schreiber, University of British Columbia

Following this session, participants will be able to:

- Understand Biliary Atresia as a rare orphan disease with neonatal onset
- Appreciate early outcome determinants on long term survival with native liver (SNL)
- Highlight management concerns for biliary atresia patients with > 20 years SNL
- Learn about potential prognostic markers at adolescence for predicting SNL in adulthood

Primary Sclerosing Cholangitis

Orlee Guttman, University of British Columbia

Aldo Montano-Loza, University of Alberta

Following this session, participants will be able to:

- Appreciate aspects of PSC that are unique in the pediatric population
- Recognize prognostic factors and screening strategies for patients with PSC

Congenital Hepatic Fibrosis in the Long-Term Outcome of Autosomal Recessive Polycystic Kidney Disease

Steven Martin, University of Calgary

Following this session, participants will be able to:

- Appreciate the natural history of congenital hepatic fibrosis (CHF) associated with Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Recognize how the CHF influences morbidity and mortality in ARPKD
- Describe the issues faced by adults with ARPKD diagnosed in childhood

3:30 – 4:30 pm | Montréal 1-3

CAHN SESSION

HCV MODELS OF CARE AMONG PRIORITY POPULATIONS: NURSING PRACTICE AND PEARLS

Chair: Mia Biondi

Following this session, participants will be able to:

- Describe models of care to enhance testing, linkage to care, and treatment of HCV infection in various population groups
- Discuss challenges and successes of establishing these HCV models of care
- Provide clinical nursing pearls in managing these various groups

Prison System

Dennaye Fuchs, Saskatchewan Health Authority

Supervised Injection and Overdose Prevention

Bernadette Lettner, South Riverdale Community Health Centre

Kate Mason, South Riverdale Community Health Centre

Reaching Homeless Populations

Jacqueline Atkinson, Mobile Outreach Street Health

Newcomer HCV Linkage

Jeanette Feizi Farivar, GI Research Institute

4:30 – 5:00 pm | Montréal 1-3

CAHN SESSION

THE NEXT LIVER DISEASE OF FOCUS: ALCOHOL OR NASH? A DEBATE

Chair: Colina Yim

David Wong, University of Toronto

Edward Tam, LAIR Centre

Following this session, participants will be able to:

- Learn about the impact of fatty liver disease and alcohol-related disease
- Advocate for patients with liver disease due to fat or alcohol

5:00 pm | Montréal 6-7

CASL ANNUAL GENERAL MEETING

CASL Members Only



CANADIAN LIVER MEETING

SUNDAY, MAY 26, 2019

7:30 am – 12:45 pm

Registration

7:30 – 9:30 am | Montréal 6-7

CAHN ANNUAL GENERAL MEETING

CAHN Members Only

8:00 – 8:50 am | Montréal 4-5

ORAL ABSTRACT PRESENTATIONS

GENERAL HEPATITIS

Vitamin E is an Effective Treatment for NASH in People Living with HIV: The CTN-PT 024 Trial

Giada Sebastiani, McGill University

Why Women Develop Less Hepatocellular Carcinoma: The Centrality of ESR1 and the Estrogen Effect

Mamatha Bhat, Multi Organ Transplant Program, UHN

CD8+ T-cell Dysfunction in a Murine Model of Liver Fibrosis

Angela M. Crawley, University of Ottawa

Implementation of a Primary Care Shear-Wave Elastography (SWE)-Based Pathway to Identify Non-Alcoholic Fatty Liver Disease (NAFLD) Patients with Advanced Fibrosis in a Large North American Urban Population

Abdel Aziz Shaheen, University of Calgary

Acyl CoA Thioesterase 1 Promotes Transition from Steatosis to Non-alcoholic Steatohepatitis

Elisa Pasini, UHN

8:50 – 9:00 am

Room Change

9:00 – 10:15 am | Montréal 4-5



CONCURRENT SESSION

END STAGE LIVER DISEASE AND LIVER TRANSPLANTATION

Referral and Optimizing Pre-Transplant in NASH/NAFLD

Giada Sebastiani, McGill University




Following this session, participants will be able to:

-  Familiarize with the main aetiologies of liver cirrhosis and associated indications to liver transplant
-  Optimize pre-transplant referral strategies in the in the specific setting of NASH/NAFLD with a better understanding of end-stage liver disease

Use of HCV + Organ in Transplant Patients

Jordan Feld, University Health Network




Following this session, participants will be able to:

-  Appreciate the successes and challenges of transplantation from HCV-infected donors to uninfected recipients
-  Determine what factors must be considered to implement use of HCV-infected donor organs
-  Discuss approaches to prevent transmission of HCV from HCV-infected donor organs

Sex and Gender Differences in Listing and Allocation for Liver Transplant

Mamatha Bhat, University of Toronto

Following this session, participants will be able to:

-  Distinguish the factors that account for sex-based disparities on the waiting list
-  Appreciate sex-based differences in organ allocation
-  Comprehend how sex-based differences impact post-transplant outcomes

10:15 – 11:15 am | St. Laurent 1-3

Break, Poster and Exhibit Viewing

SUNDAY, May 26, 2019 continued

9:00 – 10:15 am | Montréal 1-3

CONCURRENT SESSION

● IMMUNE CONTROL / DYSFUNCTION AND LIVER DISEASE

Visualizing the Immune Response in Healthy and Fatty Liver in Live Mice

Craig Jenne, University of Calgary

Following this session, participants will be able to:

- State the differences and technical limitations of various models of NAFLD in mice
- Describe the immunological changes occurring in the liver during NAFLD progression
- Discuss how pathological changes associated with NAFLD impact blood flow and pathogen capture within the liver of NAFLD mice

Mechanisms Linking Coagulation to Pro-Repair and Macrophage Activation in Acute Liver Injury

James Luyendyk, Michigan State University

Following this session, participants will be able to:

- Describe the basic mechanisms linking hepatotoxicity to intrahepatic coagulation
- Recognize the fundamentals framing the role of macrophages in liver repair
- Define basic mechanisms linking the clotting protein fibrin(ogen) to macrophage function in the injured liver

Novel HBV Tests and Diagnostics

Carla Osiowy, Public Health Agency of Canada

Following this session, participants will be able to:

- Discuss the new HBV biomarker tests that are being developed or are currently available
- Indicate how these tests may be utilized in clinical practice
- Assess gaps in our understanding of new biomarker test results

Progression Towards a Functional Cure for Hepatitis B

Norah Terrault, Keck School of Medicine, USC

Following this session, participants will be able to:

- Define functional cure and its frequency with current HBV therapies
- Enumerate clinical strategies to improve rates of functional cure with current HBV therapies
- Restate the new drug classes in development and those furthest along in clinical trials

10:15 – 11:15 am | St. Laurent 1-3

Break, Poster and Exhibit Viewing

11:15 – 12:45 pm | Montréal 4-5

GOLD MEDAL LECTURE

● UPDATES ON THE TREATMENTS OF ASCITES AND HEPATORENAL SYNDROME

Florence Wong, University Health Network Toronto

Following this session, participants will be able to:

- Distinguish between the pathophysiology of ascites formation and acute kidney injury in cirrhosis
- Identify the latest treatment options for ascites and renal failure in cirrhosis

12:00 – 12:45 pm | Montréal 4-5

● CASL AWARDS AND CONFERENCE CLOSING

Thank you for attending the 2019 Canadian Liver Meeting!

Grab your lunch-to-go on your way out.



SPONSORS

PLATINUM SPONSORS





SILVER SPONSOR





BRONZE SPONSORS




PATRON SPONSORS











The organizations listed above have kindly sponsored CLM 2019. Sponsorship is offered as an unconditional grant. The sponsors have no control over content, tone, emphasis, allocation of funds, or selection of recipients. CLM does not endorse or promote any healthcare related products.



CANADIAN
LIVER
MEETING